<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453528</url>
  </required_header>
  <id_info>
    <org_study_id>IRST100.34</org_study_id>
    <nct_id>NCT03453528</nct_id>
  </id_info>
  <brief_title>Investigation of 68GaPSMA PET/CT as an Imaging Biomarker in Solid Tumors</brief_title>
  <acronym>BASKET GA-PSMA</acronym>
  <official_title>Investigation of 68GaPSMA Positron Emission Tomography (PET)/CT as an Imaging Biomarker in Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-centre, prospective, diagnostic trial to evaluate the Prostate-Specific Membrane&#xD;
      Antigen (PSMA-antigen) over-expression in metastatic castration resistant prostate cancer&#xD;
      (mCRPC) and in advanced/metastatic solid tumors patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-centre, prospective, diagnostic trial to evaluate the Prostate-Specific Membrane&#xD;
      Antigen (PSMA-antigen) over-expression in metastatic castration resistant prostate cancer&#xD;
      (mCRPC) and in advanced/metastatic solid tumors patients.&#xD;
&#xD;
      The primary objective of this study is to evaluate the detection rate of 68Ga-PSMA PET/CT,&#xD;
      defined as the ratio of 68Ga-PSMA-positive patients and the total number of cancer patients&#xD;
      with known advanced/metastatic disease that performed a 68Ga-PSMA PET/CT as part of the&#xD;
      present study. A positive patient is defined as a patient with at least one&#xD;
      68Ga-PSMA-positive lesion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>detection rate of 68Ga-PSMA PET/CT</measure>
    <time_frame>up to 36 months</time_frame>
    <description>the proportion of 68Ga-PSMA- positive patients and the total number of recruited patients in two groups population's (metastatic castration-resistance prostate cancer and various origin solid tumors).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Safety is defined as the number and percentage of treated patients undergoing grade 1 to 4 adverse events according to CTCAE version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion detection rate stratified per tumor histotypes</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Proportion of positive patients on total number who underwent 68Ga-PSMA PET/CT stratified for tumor histotypes;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion detection rate stratified for different lesion sites</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Proportion of positive patients on total number who underwent 68Ga-PSMA PET/CT stratified for different lesion sites;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in 68Ga-PSMA uptake in patients with other solid tumors who receive anti-angiogenetic therapies according to objective clinical response;</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Changes in 68Ga-PSMA uptake in patients and correlation with clinical response to 177Lu-PSMA therapy for prostate cancer, or other angiogenic therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Prostate-specific Membrane Antigen</condition>
  <condition>mCRPC or Advanced/Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>68Ga-PSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>68Ga-PSMA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-PSMA</intervention_name>
    <description>68Ga-PSMA will be injected intravenously via an indwelling catheter in an antecubital vein; (68Ga-PSMA activity: min 100 MBq - max 200 MBq, weighted activity: 2.0 MBq/Kg).</description>
    <arm_group_label>68Ga-PSMA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with mCRPC or advanced/metastatic solid tumors;&#xD;
&#xD;
          2. Male or Female, aged &gt;18 years;&#xD;
&#xD;
          3. Written informed consent;&#xD;
&#xD;
          4. Relapse or progression of disease on CT scan and / or MRI;&#xD;
&#xD;
          5. If female of childbearing potential, highly effective birth control methods according&#xD;
             to guideline &quot;Recommendation related to contraception and pregnancy testing in&#xD;
             clinical trials&quot; (2014_09_15 section 4.1) are mandatory, beginning at the screening&#xD;
             visit and continuing until 6 months following last 68Ga-PSMA PET/CT.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy / Nursing;&#xD;
&#xD;
          2. Participation in another clinical trial with any investigational agents within 30 days&#xD;
             prior to study entry&#xD;
&#xD;
          3. Medical or psychological conditions that would not allow the participant to&#xD;
             understand, or sign the informed consent.&#xD;
&#xD;
          4. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to 68Ga-PSMA or other agents used in the study.&#xD;
&#xD;
          5. inability to remain still for the entire duration of the exam&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paola Caroli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>IRST IRCCS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oriana Nanni</last_name>
    <phone>+390543739266</phone>
    <email>oriana.nanni@irst.emr.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Caroli, MD</last_name>
      <phone>0543739100</phone>
      <email>paola.caroli@irst.emr.it</email>
    </contact>
    <investigator>
      <last_name>Federica Matteucci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 27, 2018</study_first_submitted>
  <study_first_submitted_qc>February 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mCRPC or advanced/metastatic solid tumors</keyword>
  <keyword>Prostate-specific membrane antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallium 68 PSMA-11</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

